In fact, GBM cell incubation with new compounds led to a dose-dependent increase in p53 protein levels, due to a reduced interaction between p53 and MDM2, and a reactivation of p53 functions, as demonstrated by the enhancement of mRNA transcription levels of p53 target genes, MDM2 and P21 (Figure 6). This evidence concerns the gene MDM2 and glioblastoma.